No IDC enclosed ultrasensitive immunoassays for TDP-43 pathology

The Defense Health Agency awarded Meso Scale Diagnostics LLC $997,807 on July 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to develop ultrasensitive immunoassays for TDP-43 pathology in amyotrophic lateral sclerosis research.

The recipient will deliver immunoassay technology targeting TDP-43 biomarkers to support ALS diagnostics and clinical investigation. The award obligates $997,807 through June 30, 2028, with place of performance in Rockville, Maryland. Meso Scale Diagnostics, a Native American-owned small business, specializes in electrochemiluminescence-based immunoassay platforms and has received prior DHA funding for ALS-related assay development, including a $704,431 grant completed in August 2025 for ALS clinical trial immunoassay work. The company's core federal portfolio emphasizes multiplex assay kits and diagnostic equipment supplied to biomedical research programs across the defense, NIH, and public health sectors, with particular concentration in Army biodefense and NIAID-funded vaccine and infectious disease research.